Newsletter | October 14, 2020

10.14.20 -- Changing The Status Quo Regarding Diversity In Clinical Trials

 
Sponsor
Magazine Content
What Is Your Biggest Concern Regarding The Biopharma Industry’s Reputation With The American People If We Don’t Have A COVID-19 Vaccine By The End Of This Year?
 

See the answer from Francois Nader, chairman of Acceleron Pharma.

Changing The Status Quo Regarding Diversity In Clinical Trials
 

Encouraging patients of all races and genders to enroll in clinical trials has been a challenge for years. So, what can be done?

Right Now, You Should Think “Coach First”
 

We’ve all seen the value that coaching can produce on performance, but traditional coaching approaches are difficult to scale and too expensive to implement.

Regulatory Content
How The FDA Is Helping Advance Clinical Trial Diversity
 

An update from the FDA Office of Minority Health and Health Equity on its efforts to address health disparities and health equity — and ultimately strengthen the agency’s ability to respond to minority health concerns.

Sponsor
Survey
What Will Happen To Business Travel In 2021? Take Our 5-Question Survey.
 
Video
ebooks
Patent Issues In Life Sciences: An Overview Of Legal Coverage Of The Topic
 

From IPR trends, to new advances in AI or medtech, to how you can protect your company from a legal perspective, patent issues are, in some way, likely on your mind as a biopharma executive. For this ebook we’ve gathered some of the most informative and educational patent-related articles that appeared in Life Science Leader during 2019 and early 2020.

October 2020 Digital Edition
 

Inside you will find more on:

  • Regulatory Issues
  • Drug Development During COVID-19
  • Market Research
  • Companies To Watch

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines
 

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.